---
schema_version: "secwatch.filing_event.v1"
accession: "0001808805-25-000069"
form_type: "8-K"
ticker: "NAUT"
cik: "0001808805"
company_name: "Nautilus Biotechnology, Inc."
filed_at: "2025-07-31T23:59:59+00:00"
generated_at: "2026-05-17T22:25:27.346852+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Nautilus Q2 net loss narrows to $15.0M; cash $179.5M; platform milestone

## Summary
- Operating expenses $17.1M, down 18% YoY from $20.8M.
- Net loss $15.0M improved from $18.0M loss in Q2 2024.
- Cash, equivalents and investments $179.5M as of June 30, 2025.
- Published first scientific manuscript validating Iterative Mapping method for proteoform measurement.
- Signed two collaborations to study Tau proteoforms in Alzheimer's disease.

## SEC filing metadata
- accession: 0001808805-25-000069
- form_type: 8-K
- ticker: NAUT
- cik: 0001808805
- company_name: Nautilus Biotechnology, Inc.
- filed_at: 2025-07-31T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808805/000180880525000069/0001808805-25-000069-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808805/000180880525000069/naut-20250731.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001808805-25-000069
- JSON: https://secwatch.observer/filing/0001808805-25-000069.json
- Plain text: https://secwatch.observer/filing/0001808805-25-000069.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.